Stock AZT ARCTICZYMES TECHNOLOGIES ASA
Add to a list
To use this feature you must be a member
Log inSign up

Company ArcticZymes Technologies ASA

Equities

AZT

NO0010014632

Biotechnology & Medical Research

Market Closed - Oslo Bors
Other stock markets
 10:45:00 2024-04-29 am EDT 		5-day change 1st Jan Change
25.9 NOK -0.38% Intraday chart for ArcticZymes Technologies ASA -0.96% -38.33%
Apr. 09 Norway's ArcticZymes Teams Up With Austrian Group for Bionanoparticles Research Project MT
Apr. 09 ArcticZymes Technologies ASA Initiates Joint Research Project with Austrian Centre of Industrial Biotechnology CI

Business Summary

Arcticzymes Technologies ASA is a Norway-based holding company providing support functions to the ArcticZymes AS subsidiary including distribution, administration, finance, Information Technology (IT) and quality assurance. As a life science company, Arcticzymes Technologies ASA is focused on the development, manufacturing, and commercialization of novel and high-quality recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. Some of the key features of the Company’s enzymes include cold activeness and salt tolerance. The Company’s divided into two operating segments; Enzymes and Corporate. Arcticzymes established logistic hubs in the United States and the Netherlands to serve its customers more efficiently.

Sales per Business

NOK in Million2021Weight2022Weight Delta
Enzymes
100.0 %
128 100.0 % 137 100.0 % +7.03%

Sales per region

NOK in Million2021Weight2022Weight Delta
United States
44.1 %
50 39.5 % 60 44.1 % +19.53%
Lithuania
20.5 %
35 27.5 % 28 20.5 % -20.20%
Other Countries in Europe
13.0 %
11 8.8 % 18 13.0 % +57.27%
Rest of World
11.5 %
16 12.8 % 16 11.5 % -3.73%
Germany
8.8 %
11 8.4 % 12 8.8 % +11.90%
Italy
1.9 %
3 2.7 % 3 1.9 % -24.56%
Norway
0.3 %
0 0.4 % 0 0.3 % -11.69%

Managers

Managers TitleAgeSince
Michael Akoh CEO
 Chief Executive Officer - 23-09-17
Børge Sørvoll DFI
 Director of Finance/CFO 49 14-09-30
Darren Ellis CTO
 Chief Tech/Sci/R&D Officer - 22-11-30
Marit Sjo Lorentzen COO
 Chief Operating Officer 56 -
Olav Lanes CTO
 Chief Tech/Sci/R&D Officer 52 99-12-31
Dirk Hahneiser SAM
 Sales & Marketing 56 21-12-31
Dino DiCamillo SAM
 Sales & Marketing 66 11-12-31

Members of the board

Members of the board TitleAgeSince
Marie Roskrow CHM
 Chairman - -
Olav Lanes CTO
 Chief Tech/Sci/R&D Officer 52 99-12-31
Marit Sjo Lorentzen COO
 Chief Operating Officer 56 -
Jane Theaker BRD
 Director/Board Member - -
Bernd Striberny BRD
 Director/Board Member - -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 50,871,390 35,904,791 ( 70.58 %) 0 70.58 %

Shareholders

NameEquities%Valuation
Swedbank Robur Fonder AB
4.384 %
2,230,000 4.384 % 6 M kr
Sjur Thorsheim
4.113 %
2,092,316 4.113 % 6 M kr
Joh. Berenberg, Gossler & Co. KG (Investment Management)
3.107 %
1,580,354 3.107 % 4 M kr
Stale Hellenes
2.087 %
1,061,892 2.087 % 3 M kr
Jon Rømer Sandberg
1.997 %
1,015,684 1.997 % 3 M kr
Tellef Ormestad
1.585 %
806,192 1.585 % 2 M kr
10xDNA Capital Partners GmbH
1.268 %
645,097 1.268 % 2 M kr
Edvard Hjort Iversen
1.204 %
612,400 1.204 % 2 M kr
Riise Invest Nord AS
1.179 %
600,000 1.179 % 2 M kr
KLP Kapitalforvaltning AS
1.100 %
559,343 1.100 % 2 M kr

Company contact information

ArcticZymes Technologies ASA

Siva Innovasjonssenter Sykehusveien 23

9019, Tromsø

+47 77 64 89 00

http://www.arcticzymes.com
address ArcticZymes Technologies ASA(AZT)

Group companies

NameCategory and Sector
ArcticZymes AS
Logo ArcticZymes AS

ArcticZymes AS

Medical SpecialtiesHealth Technology

Part of ArcticZymes Technologies ASA, ArcticZymes AS is a Norwegian company that manufactures diagnostic substances. The private company is based in Tromsø, Norway. Jethro Holter has been the CEO of the company since 2015.

Medical Specialties
Biotec BetaGlucans AS
Logo Biotec BetaGlucans AS

Biotec BetaGlucans AS

Pharmaceuticals: MajorHealth Technology

Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The private company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million.

Pharmaceuticals: Major

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per Business

Sales per region

Ratings for ArcticZymes Technologies ASA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
26 NOK
Average target price
32 NOK
Spread / Average Target
+23.08%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ARCTICZYMES TECHNOLOGIES ASA Stock ArcticZymes Technologies ASA
-38.33% 120M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+2.48% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+47.92% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+11.98% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.21% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.00% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.83% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.91% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.95% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. AZT Stock
  4. Company ArcticZymes Technologies ASA